<DOC>
	<DOCNO>NCT00004358</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether intermittent , long-term , subcutaneous administration calcitonin increase phosphaturia , reduces hyperphosphatemia , increase intact parathyroid hormone level patient tumoral calcinosis . II . Determine whether calcitonin reduces prevents tumor recurrence . III . Determine whether hyperphosphatemia abolishes normal circadian pattern serum phosphorus . IV . Determine repetitive calcitonin administration alters biochemical marker bone metabolism osteopenic patient tumoral calcinosis .</brief_summary>
	<brief_title>Phase II Study Calcitonin Tumoral Calcinosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat subcutaneous injection salmon calcitonin every 3 week . Ondansetron premedication intravenous hydration also administer . Patients follow disease progression tumor recurrence .</detailed_description>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm tumoral calcinosis Prior/Concurrent Therapy Prior surgical resection calcinotic lesion require</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>rare disease</keyword>
	<keyword>tumoral calcinosis</keyword>
</DOC>